Share on LinkedInShare on LinkedIn

ARTICLE · 22 JUNE 2017

Supreme Court Interprets BPCIA Disclosure And Notice Provisions

On June 12, 2017, in a unanimous decision, the Supreme Court of the United States decided Sandoz Inc. v. Amgen Inc., which concerned certain disclosure and notice requirements imposed by the of BPCIA 2009...

United StatesIntellectual Property

On June 12, 2017, in a unanimous decision, the Supreme Court of the United States decided Sandoz Inc. v. Amgen Inc., which concerned certain disclosure and notice requirements imposed by the Biologics Price Competition and Innovation Act of 2009 ("BPCIA"), 42 U.S.C. § 262(l), on applicants seeking FDA approval for biosimilars of biologic drug products. The BPCIA is a "complex statutory scheme" that "establishes processes both for obtaining FDA approval of biosimilars and for resolving patent disputes between manufacturers of licensed biologics and manufacturers of biosimilars." In particular, the Court resolved two issues concerning the BPCIA, holding that (i) an injunction is not an available remedy under federal law to force a biosimilar applicant to provide a copy of its FDA application and information about how the biosimilar is manufactured to the manufacturer of a licensed biologic product prior to the start of a patent infringement case; and (ii) an applicant

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from